Such antibodies have been developed to be directed against VEGF and Ang-2, a molecule that promotes invasiveness and angiogenesis, and these have proved effective at reprogramming the tumor microenvironment and extending survival in mouse xenograft models (Kloepper and others 2016). Here, VEGFA is linked to neoplasm.